Jayaram R. Tagat

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

Alexandra Trkola, Shawn E. Kuhmann, Julie Strizki et al. · Proceedings of the National Academy of Sciences · 2002 · 303 citations · Full text

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection<i>in vitro</i>and<i>in vivo</i>

Julie Strizki, Serena Xu, Nicole Wagner et al. · Proceedings of the National Academy of Sciences · 2001 · 300 citations · Full text

Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1

Julie Strizki, Cécile Tremblay, Serena Xu et al. · Antimicrobial Agents and Chemotherapy · 2005 · 214 citations · Full text

Antiviral Compound, Neurovirology, Medicine +15

Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry

Fotini Tsamis, Svetlana Gavrilov, Francis Kajumo et al. · Journal of Virology · 2003 · 204 citations · Full text

Ccr5 Function, Immunology, Molecular Biology +16

Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. IV. Discovery of 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-{2-methoxy-1(<i>R</i>)-4-(trifluoromethyl)phenyl}ethyl-3(<i>S</i>)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a Potent, Highly Selective, and Orally Bioavailable CCR5 Antagonist

Jayaram R. Tagat, Stuart W. McCombie, Dennis V. Nazareno et al. · Journal of Medicinal Chemistry · 2004 · 136 citations · Full text

Excellent Receptor Selectivity, Immunology, Hiv-1 Inhibitors +19